|
gptkbp:instanceOf
|
gptkb:drug
aromatase inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
1996
|
|
gptkbp:ATCCode
|
L02BG04
|
|
gptkbp:brand
|
gptkb:Femara
|
|
gptkbp:CASNumber
|
gptkb:112809-51-5
|
|
gptkbp:chemicalClass
|
triazole
|
|
gptkbp:contraindication
|
pregnancy
pre-menopausal women (for breast cancer)
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:discoveredBy
|
gptkb:Ciba-Geigy
|
|
gptkbp:eliminationHalfLife
|
2 days
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C17H11N5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
letrozole
|
|
gptkbp:KEGGID
|
D08113
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits aromatase enzyme
|
|
gptkbp:meltingPoint
|
184-185°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
X (contraindicated)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL960
3902
DB01006
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:bone
fatigue
joint pain
hot flashes
|
|
gptkbp:synonym
|
gptkb:Femara
gptkb:CGS_20267
|
|
gptkbp:UNII
|
T6X3TUE4A8
|
|
gptkbp:usedFor
|
gptkb:cancer
ovulation induction
|
|
gptkbp:bfsParent
|
gptkb:Femara
|
|
gptkbp:bfsLayer
|
5
|